Angela K. Talley, MD

Vice President, Clinical Development
Spero Therapeutics

Disclosure: Spero Therapeutics (Employee, Shareholder)

Angela Talley, MD is the Vice President of Clinical Development at Spero Therapeutics in Cambridge, MA. Prior to joining Spero Therapeutics, she was Executive Director of Clinical Development for Anti-Infectives at Allergan, plc, where she led clinical development activities across multiple anti-infective programs (ceftazidime-avibactam, aztreonam-avibactam, ceftaroline) since 2015 and, prior to this, held similar roles for related development programs at Cerexa, Inc (a subsidiary of Forest Laboratories). She received her medical degree from the Mount Sinai School of Medicine in New York, NY. She completed residency in Internal Medicine at Columbia-Presbyterian Medical Center in New York, NY and subsequently completed Infectious Disease fellowship training at the University of Washington in Seattle, WA. Dr. Talley has over 15 years of clinical research and drug development experience for the anti-infective therapeutic area in both academic and industry settings.